Preventing Relapse: The Role of LAIs in Schizophrenia
About this episode
This episode discusses the use of long-acting injectable antipsychotics in the treatment of schizophrenia, focusing on indications, candidate profiles, and shared decision-making.
In this episode, we explore when and why long-acting injectable antipsychotics (LAIs) should be considered for patients with schizophrenia, covering approved indications, ideal candidate profiles, and the critical role of shared decision-making in treatment planning. Faculty: Brian Miller, M.D., Ph.D., M.P.H. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Use of Long-Acting Injectable Antipsychotics in Schizophrenia Understanding When to Prescribe LAIs
More episodes of Psychopharmacology and Psychiatry Updates
- Is High-Dose Olanzapine A Clozapine Alternative?
- CANMAT Guidelines: Herbs, Supplements, and Depression
- Xylazine in the ED: Managing Toxicity
- Choosing the First Step in Depression Treatment: A CANMAT Guide
- After Delirium Clears: When to Deprescribe?
- The Clinician's Guide to Paliperidone & Risperidone LAIs
Explore listener stats, chart rankings, contacts and more on the Psychopharmacology and Psychiatry Updates podcast page.